{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=36", "query": { "condition": "Multiple Myeloma", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 2318, "total_pages": 232, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T09:15:23.435Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07217184", "title": "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-07-29", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217184" }, { "nct_id": "NCT00991562", "title": "IMGN901 in Combination With Lenalidomide and Dexamethasone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "IMGN901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-12", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-21", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 9, "location_summary": "Los Angeles, California • Palm Springs, California • Sarasota, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991562" }, { "nct_id": "NCT00973804", "title": "Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Non-Hodgkins Lymphoma", "Hodgkins Lymphoma", "MDS", "Multiple Myeloma" ], "interventions": [ { "name": "EPOCH-F/R", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "Transplant Preparative Regimen (Flu/Cy/Mes)", "type": "DRUG" }, { "name": "GVHD Prophylaxis (tacrolimus and sirolimus)", "type": "DRUG" }, { "name": "Double Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 4, "start_date": "2009-08-25", "completion_date": "2013-05-20", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00973804" }, { "nct_id": "NCT01132833", "title": "Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma", "Plasma Cell Neoplasm", "Thromboembolism" ], "interventions": [ { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2008-12", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-08-22", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132833" }, { "nct_id": "NCT03221634", "title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-08-01", "completion_date": "2021-06-10", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 3, "location_summary": "Jacksonville, Florida • Atlanta, Georgia • Bloomfield Hills, Michigan", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Bloomfield Hills", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03221634" }, { "nct_id": "NCT01892293", "title": "CT Antigen TCR-Engineered T Cells for Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Treatment with NY-ESO-1c259-modified T cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adaptimmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 6, "start_date": "2013-10-15", "completion_date": "2018-04-09", "has_results": true, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 2, "location_summary": "Duarte, California • Baltimore, Maryland", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01892293" }, { "nct_id": "NCT06799026", "title": "A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "DC/MM Fusion Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "David Avigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-01-31", "completion_date": "2030-09-01", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799026" }, { "nct_id": "NCT04887259", "title": "Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Multiple Myeloma", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "LAVA-051", "type": "BIOLOGICAL" }, { "name": "Interleukin 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lava Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-07-12", "completion_date": "2023-09-06", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 5, "location_summary": "Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887259" }, { "nct_id": "NCT02195479", "title": "A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Daratumumab IV", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 706, "start_date": "2014-12-09", "completion_date": "2024-08-07", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 10, "location_summary": "California City, California • Corona, California • Fountain Valley, California + 7 more", "locations": [ { "city": "California City", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02195479" }, { "nct_id": "NCT01496118", "title": "Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "panobinostat", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-12", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2022-02-02", "last_synced_at": "2026-10-29T09:15:23.435Z", "location_count": 13, "location_summary": "Denver, Colorado • Fort Myers, Florida • Pensacola, Florida + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496118" } ] }